FDA shifts toward reduced-risk vaping products amid criticism
A former congressman and physician argues that the FDA is finally approving less-harmful nicotine alternatives, which could cut smoking rates.
Smoking continues to be the leading cause of preventable illness, according to a former congressman who spent his career on health policy. He recalls that the 2009 law gave the FDA authority over tobacco with a dual goal: reduce disease while preserving adult choice. After years of rejecting the vast majority of vapor-product applications, the agency inadvertently expanded the black-market share to 70-80 percent.
The FDA has now authorized flavored vaping devices and nicotine pouches, which public-health experts estimate cut risk by 95 percent or more. The writer urges the agency to adopt transparent product standards, speed up reviews, and launch outreach to adults and clinicians to dispel alarmist views. He also stresses that youth vaping is rare and declining, and that responsible retail practices can further limit under-age access. Ultimately, he supports the FDA’s new approach as a means to lower smoking-related disease among the 28 million adult smokers in the United States.
Why it matters
FDA approval of safer nicotine products could dramatically reduce smoking-related illness and health costs.
In this story
